Haemonetics
Corporate brand
UnclaimedGlobal medical technology company focused on blood collection, processing, transfusion medicine, and patient blood management.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Haemonetics Corporation is a United States medical technology company whose products and services support the collection, processing, management, and clinical use of blood and blood components. The company serves blood centers, plasma collection organizations, hospitals, surgical teams, and other healthcare providers. Its portfolio spans donor-facing systems, blood component separation, plasma collection, transfusion-related technologies, surgical blood salvage, blood and patient warming, blood-management software, and hemostasis testing. The company was established in 1971 in Natick, Massachusetts, by Dr. Allen (Jack) Latham. Its early business centered on containers and bags used for blood collection. A significant early innovation was the Latham Bowl, a disposable centrifugation container designed to automate the separation of whole blood into components. This helped establish the company's role in blood-processing equipment and consumables rather than limiting it to conventional collection supplies. Haemonetics expanded its manufacturing and product base during the 1980s and 1990s. It opened a manufacturing facility in Holbrook, Massachusetts, in 1988 and acquired an intravenous-solutions manufacturing facility in Union, South Carolina, in 1995. During the 1990s and afterward, the company broadened its offering from individual collection components toward integrated blood and plasma collection stations that combined equipment, disposable supplies, and software. A series of acquisitions extended Haemonetics' capabilities in information systems, surgical blood management, hemostasis, and transfusion medicine. Purchases and investments involving Fifth Dimension Information Systems, Information Data Management, Arryx, Haemoscope, Infonale, Altivation, Sebra, Neoteric Technology, and Global Med Technologies added software, testing, automation, and blood-bank technologies. In 2007, Fifth Dimension and Information Data Management were combined into Haemonetics Software Solutions, linking the company's operational technology with its blood and plasma-management activities. The acquisition of Pall Corporation's transfusion medicine business in 2012 was another major expansion, adding products and capabilities in filtration and transfusion-related care. The company divides its activities broadly between donor products and hospital or surgical products. Donor products help automate blood and plasma collection, separate blood components, support pathogen and bacterial-control workflows, and measure blood characteristics such as hematocrit. Surgical and patient-blood-management products address blood loss, recovery, reinfusion, suction, warming, and coagulation assessment. The TEG family of hemostasis analyzers is used to evaluate clot formation and platelet-related function in clinical settings. Haemonetics operates internationally, with offices in multiple countries and products marketed across more than 50 countries according to the cited encyclopedia reference. Its business is organized around specialized healthcare workflows in which equipment, single-use consumables, software, and clinical data-management tools are often used together. In April 2024, the company completed its acquisition of Attune Medical, a Chicago-headquartered manufacturer focused on medical-device temperature regulation, further broadening its patient-blood-management and perioperative technology portfolio. Haemonetics remains an active publicly traded medical-device company headquartered in Boston.
History
Haemonetics was founded in 1971 in Natick, Massachusetts, by Dr. Allen (Jack) Latham. The company initially concentrated on the physical supplies needed to collect blood, including containers and bags. Its early development of the Latham Bowl gave the company a distinctive technological foundation: the disposable bowl enabled blood to be separated by centrifugation as part of an automated collection and processing workflow. This approach positioned Haemonetics within the emerging field of blood-component therapy, in which whole blood could be separated into components for more targeted clinical use. The company expanded its industrial base during the 1980s. In 1988 it opened a manufacturing facility in Holbrook, Massachusetts. In 1995 it acquired an intravenous-solutions manufacturing facility in Union, South Carolina, extending its production capabilities and physical footprint. During the 1990s, Haemonetics added product lines and technologies beyond its original collection supplies, gradually developing a broader platform for blood processing and transfusion-related operations. A later phase of growth came through acquisitions in software, automation, blood-bank management, and clinical diagnostics. The company acquired Edmonton-based Fifth Dimension Information Systems to enter the blood and plasma software market. It subsequently acquired Chicago-based Arryx in July 2006, Information Data Management in January 2007, a division of Haemoscope in 2007, and Infonale in July 2007. In August 2007, Fifth Dimension and Information Data Management were formally combined as Haemonetics Software Solutions. The two organizations continued operating from their existing Edmonton and Rosemont locations while becoming part of a unified software subsidiary. Haemonetics continued its expansion in 2009 through acquisitions of Altivation, based in Chico, California, and Sebra, based in Tucson, Arizona. In April 2009 it also acquired Neoteric Technology, adding further blood-management and automation capabilities. In April 2010, the acquisition of Global Med Technologies expanded the company's presence in blood-bank information and related technology. These transactions reflected a strategy of building an integrated offering that could include collection machines, single-use supplies, software, testing, and operational systems. On August 1, 2012, Haemonetics acquired Pall Corporation's transfusion-medicine business for approximately $550 million. The transaction significantly strengthened the company's transfusion-related portfolio and broadened its role in blood-component processing and clinical delivery. Alongside its donor products, Haemonetics maintained a growing surgical and hospital business, including autotransfusion equipment, surgical suction, blood and patient warming, and hemostasis testing. The company's products are generally organized into two broad areas. Donor products support blood and plasma collection, component separation, pathogen inactivation, bacterial detection, and hematocrit testing. Surgical and patient-blood-management products address blood lost during procedures, recovery and reinfusion of a patient's own blood, surgical-field suction, temperature management, and assessment of coagulation. The TEG family, including systems and assays such as TEG 5000, Kaolin TEG, RapidTEG, Functional Fibrinogen, PlateletMapping, and TEG 6S, represents the company's hemostasis-testing activities. Haemonetics has developed an international operating footprint, with offices in multiple countries and products sold in more than 50 countries according to the cited reference. Its markets include the Americas, Europe, and Asia. In April 2024, it completed the acquisition of Attune Medical for $160 million. Attune Medical is headquartered in Chicago and manufactures medical devices for temperature regulation. The transaction continued Haemonetics' expansion into technologies associated with patient management and perioperative care. The company is currently an active publicly traded medical-technology business headquartered in Boston.
- 2024
Attune Medical acquisition completed
[1]Haemonetics completed the acquisition of Attune Medical, a medical-device manufacturer focused on temperature regulation, for $160 million.
- 2012
Pall transfusion-medicine business acquired
[1]Haemonetics acquired Pall Corporation's transfusion-medicine business for approximately $550 million.
- 2010
Global Med Technologies acquired
[1]Haemonetics acquired California-based Global Med Technologies, expanding its blood-bank and information-technology capabilities.
- 2009
Neoteric Technology and other businesses acquired
[1]The company acquired Neoteric Technology and also added Altivation and Sebra to its portfolio.
- 2007
Software subsidiary formed
[1]Fifth Dimension Information Systems and Information Data Management were merged into Haemonetics Software Solutions.
- 2006
Arryx acquired
[1]Haemonetics acquired Chicago-based Arryx as part of its expansion into related technology capabilities.
- 1995
Union, South Carolina facility acquired
[1]Haemonetics acquired an intravenous-solutions manufacturing facility in Union, South Carolina.
- 1988
Holbrook manufacturing facility opened
[1]The company opened a manufacturing facility in Holbrook, Massachusetts.
- 1971
Company founded
[1]Haemonetics was founded in Natick, Massachusetts, by Dr. Allen (Jack) Latham.
Products and positioning
Specialized medical-device and healthcare-technology supplier focused on blood management across donation, plasma collection, transfusion medicine, surgery, and patient blood management.
Blood component collection
MCS+
The MCS+ family consists of automated blood component collection systems used in donor settings. These systems support the collection of selected components, such as platelets or plasma, while separating blood during the donation process. They are part of Haemonetics' donor-product portfolio and are designed to integrate collection equipment with disposable blood-processing components.
Plasma collection
PCS2
PCS2 is a plasma-collection system intended for automated plasmapheresis workflows. It combines collection equipment with disposable supplies to separate and collect plasma from a donor while returning other blood components. The system represents Haemonetics' broader effort to provide complete plasma-collection stations rather than isolated consumables.
Hemostasis testing
TEG 5000
TEG 5000 is a viscoelastic hemostasis analyzer used to assess the dynamics of clot formation and dissolution. It is designed to provide clinicians with functional information about coagulation and fibrinolysis that can support blood-management decisions in surgical and critical-care environments.
Hemostasis testing
TEG 6S
TEG 6S is part of Haemonetics' TEG family of hemostasis-analysis systems. It is used for point-of-care evaluation of clotting performance and related blood-management decisions. The platform belongs to the company's hospital and surgical portfolio and complements its donor and transfusion technologies.
Patient blood management
Surgical blood-salvage systems
Haemonetics' surgical blood-salvage or autotransfusion products are used to collect, process, and return a patient's own blood during or after surgery. These systems are intended to support blood conservation by making recovered blood available for reinfusion when clinically appropriate.
Temperature management · 2024
Blood and patient warming systems
Blood and patient warming technologies support temperature management during transfusion, surgery, and other clinical procedures. Haemonetics expanded this area through its 2024 acquisition of Attune Medical, adding temperature-regulation devices to its patient-blood-management portfolio.
Transfusion medicine · 2012
Transfusion-medicine products
The transfusion-medicine portfolio includes products used in the processing, filtration, and clinical management of blood components. The business was materially expanded through Haemonetics' acquisition of Pall Corporation's transfusion-medicine business in 2012.
Brand decisions
2024
Acquisition of Attune MedicalM&ABackground
Haemonetics pursued additional capabilities in medical-device temperature regulation and patient blood management.
Action taken
The company completed its acquisition of Chicago-based Attune Medical in April 2024 for $160 million.
Aftermath
Attune Medical's temperature-regulation technology became part of Haemonetics' broader patient-management and perioperative portfolio.
Acquisition price. $160 million (April 2024)
2012
Acquisition of Pall Corporation's transfusion-medicine businessM&ABackground
Haemonetics sought to expand its transfusion-medicine offering and strengthen its position across blood-component processing and clinical transfusion workflows.
Action taken
The company acquired Pall Corporation's transfusion-medicine business on August 1, 2012, in a transaction reported at approximately $550 million.
Aftermath
The acquisition broadened Haemonetics' transfusion-related product portfolio and added to its integrated blood-management strategy.
Acquisition price. $550 million (2012)
Recent events
- Unconfirmed
Reported
CSL expects to complete U.S. rollout of Haemonetics plasmapheresis platform by end of 2027[3]
CSL expects to complete the rollout of Haemonetics' plasmapheresis platform across the United States by the end of 2027. Haemonetics shares popped 8% in premarket trading on the news.
Reported
Haemonetics agrees to acquire Cardiva Medical[4]
Haemonetics said it had agreed to acquire Cardiva Medical for $475 million in cash upfront; the deal was expected to close in the first quarter of 2021.
Reported
Haemonetics announced sale of Puerto Rico manufacturing operations to GVS[5]
Haemonetics announced a definitive agreement to sell its Fajardo, Puerto Rico manufacturing operations to GVS. The proposed transaction includes certain operating assets; Haemonetics would retain the intellectual property rights to its proprietary blood filters.
Reported
Haemonetics and GVS announced planned blood-filter supply and development collaboration[5]
Haemonetics and GVS announced that, in connection with the proposed sale, they will enter into a long-term supply and development agreement. The agreement is to grant GVS exclusive rights to manufacture and supply the blood filters currently produced at Haemonetics' Fajardo facility for Haemonetics.
Reported
Haemonetics agrees to sell blood donor software assets to GPI[6]
Haemonetics announced a definitive agreement to sell certain blood donor management software solution assets to the GPI Group. The transaction was expected to close in the second quarter of 2020, subject to customary closing conditions.
Reported
Haemonetics acquires enicor GmbH[7]
Haemonetics announced that it had acquired all of the outstanding share capital of enicor GmbH, a Munich-based manufacturer of the ClotPro whole-blood coagulation testing system.
Reported
Haemonetics acquires TEG 6s intellectual property[8]
Haemonetics announced that it purchased the technology underlying the TEG 6s Hemostasis Analyzer System from CoraMed Technologies and acquired ownership of related intellectual property.
Sources8 sources
- 1Haemoneticsen.wikipedia.org
- 2Haemonetics official websitehaemonetics.com
- 3CSL 预计2027年底前完成 Haemonetics 血浆单采平台全美推广cnbc.com
- 4Haemonetics同意收购Cardiva Medicalbostonglobe.com
- 5Haemonetics宣布出售波多黎各制造业务给GVSprnewswire.com
- 6Haemonetics同意向GPI出售血液捐献者管理软件资产prnewswire.com
- 7Haemonetics收购enicor GmbHprnewswire.com
- 8Haemonetics 收购 TEG 6s 智慧财产权prnewswire.com
Cite this profile: Cite the canonical profile. /brand-wiki/haemonetics · Editorial policy · How profiles are compiled